Regenerex Pharma (RGPX) Operating Expenses (2010 - 2025)

Regenerex Pharma (RGPX) has 14 years of Operating Expenses data on file, last reported at $786709.0 in Q3 2025.

• Operating Expenses for Q3 2025 came in at $786709.0, up 204.47% year-over-year; the trailing twelve-month figure through Sep 2025 was $2.7 million (up 164.81% YoY), and the FY2025 annual result was $1.8 million, down 47.31% from the prior year.
• Operating Expenses grew to $786709.0 in Q3 2025 per RGPX's latest filing, from $633783.0 in the prior quarter.
• Over five years, Operating Expenses peaked at $2.8 million in Q3 2023 and troughed at $11688.0 in Q2 2021.
• A 5-year average of $385269.5 and a median of $199779.0 in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses soared 12855.37% in 2023, then slumped 90.73% in 2024.
• A 5-year view of Operating Expenses shows it stood at $61975.0 in 2021, then slumped by 53.04% to $29102.0 in 2022, then soared by 722.57% to $239384.0 in 2023, then surged by 30.13% to $311510.0 in 2024, then jumped by 152.55% to $786709.0 in 2025.
• Business Quant data shows RGPX's Operating Expenses at $786709.0 in Q3 2025, $633783.0 in Q2 2025, and $1.0 million in Q1 2025.